Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + TheraSphere
- Development stage
- Unknown
- Lead developer
- Boston Scientific
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intra-arterial
01
Overview
A combination therapy consisting of gemcitabine, a nucleoside analog chemotherapeutic agent, and TheraSphere, a yttrium-90 (Y-90) glass microsphere radioembolization treatment. This combination approach aims to provide both systemic chemotherapy via gemcitabine and targeted radiation therapy to liver tumors through TheraSphere. It has been investigated in clinical trials for treating hepatic metastases from pancreatic cancer and intrahepatic cholangiocarcinoma.
- Brand names
- Gemzar
- Other names
- Gemcitabine with TheraSphereGemcitabine + Y-90 TheraSphereGemcitabine plus yttrium-90 radioembolization
02
Targets
DNA polymerase familyENT (Equilibrative nucleoside transporter family)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + TheraSphere.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + TheraSphere.